anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention discloses a sterilization ointment capable of quickly killing acquired immunodeficiency syndrome viruses, venereal disease viruses and sperms and a preparation method thereof. The sterilization ointment is colorless, tasteless, water soluble and transparent liquid in an ointment shape which is prepared by refining octoxynol, aloe, benzalkonii chloridum, etc. used as main raw materials through certain technologies. Through the confirmation of six authority departments, such as the acquired immunodeficiency syndrome research and detection center of Chinese academy of preventive medicine, the national center for venereal disease leprosy control, etc., the present invention can kill acquired immunodeficiency syndrome viruses within 15 minutes in sexual life, kill various venereal disease sources, such as gonococci, treponema pallida, vaginitis, trichomonas vaginalis, etc., within 1 minute, and kill human body sperms within 1 minute. The sterilization ointment of the present invention can make men and women contracept in sexual contact, thoroughly block the infection of acquired immunodeficiency syndromes and venereal diseases, and achieve the optimum effects of infection prevention, effective venereal disease propagation blockage, effective acquired immunodeficiency syndrome propagation blockage, effective venereal disease diffusion blockage and effective acquired immunodeficiency syndrome diffusion blockage. The sterilization ointment of the present invention has the advantages of bidirectional protection, happy emotion expression, no toxin, no harm, long 8 hour medicine effect, safety and reliability.
The invention discloses a traditional Chinese medicinal composition for treating neurodermatitis. The traditional Chinese medicinal composition is prepared from cicada slough, lotus leaves, lilies, goldthread, radix sophorae flavescentis, poria cocos, dried tangerine or orange peels, grapefruit leaves, honeysuckles, field bindweed, plumbagella micrantha, broom cypress fruits, antigramma sibiricus J. Sm., coix seeds, elsholtzia cypriani, lodestone, tremella, snake gourd fruits, horsetail, flatstem milkvetch seeds, the roots of kudzu vines, Chinese dates, Chinese wolfberries, motherwort and pseudo-ginseng. The invention further discloses a preparation method of the traditional Chinese medicinal composition. Compared with drugs for treating the neurodermatitis in the prior art, the traditional Chinese medicinal composition has the advantages of good curative effect on the neurodermatitis, low cost, high cure rate, small limitation, non-existence of untoward effects and the like; the traditional Chinese medicinal composition can relieve illness conditions quickly and has few toxic and side effects. The raw materials of the traditional Chinese medicinal composition are cheap and easy to get, the traditional Chinese medicinal composition is easy to prepare, safe in clinical application, free from toxic and side effects and good in neurodermatitis curative effect, and quick action is achieved.
PURPOSE: To obtain the subject solution effective for preventing the damage to hair, restoring damaged hair, giving excellently waved hair and having storage stability by compounding a specific silylated peptide to the 1st solution for permanent wave treatment containing a reducing agent as a main component. CONSTITUTION: This 1st solution for permanent wave treatment is produced by compounding a 1st solution for permanent wave treatment containing a reducing agent as a main component with a silylated peptide having a functional group containing only one Si atom and bonded through covalent bond to the amino group of a peptide containing an amino group of an amino acid side chain. The silylated peptide is preferably the compound of formula I (R<1> to R<3> are each a 1-3C alkyl or OH; R<4> is a residue obtained by removing the terminal amino group from a basic amino acid having amino group on the terminal of a side chain; R<5> is an amino acid side chain other than R<4> ; (a) is 1 or 3, (m) and (n) are each 0-200; m+n is 1-200) or formula II. The compounding amount of the compound is preferably 0.1-15wt.%.  The system is preferably further compounded with 0.1-5wt.% of a cationic surfactant. The agent imparts the hair with luster and moist feeling, gives smooth hair and prevents the generation of split hair and cut hair.
BACKGROUND: Migraine is a debilitating neurological disorder with pain profile, suggesting exaggerated mechanosensation. Mechanosensitive receptors of different families, which specifically respond to various mechanical stimuli, have gathered increasing attention due to their potential role in migraine related nociception. Understanding these mechanisms is of principal importance for improved therapeutic strategies. This systematic review comprehensively examines the involvement of mechanosensitive mechanisms in migraine pain pathways.
METHODS: A systematic search across the Cochrane Library, Scopus, Web of Science, and Medline was conducted on 8th August 2023 for the period from 2000 to 2023, according to PRISMA guidelines. The review was constructed following a meticulous evaluation by two authors who independently applied rigorous inclusion criteria and quality assessments to the selected studies, upon which all authors collectively wrote the review.
RESULTS: We identified 36 relevant studies with our analysis. Additionally, 3 more studies were selected by literature search. The 39 papers included in this systematic review cover the role of the putative mechanosensitive Piezo and K2P, as well as ASICs, NMDA, and TRP family of channels in the migraine pain cascade. The outcome of the available knowledge, including mainly preclinical animal models of migraine and few clinical studies, underscores the intricate relationship between mechanosensitive receptors and migraine pain symptoms. The review presents the mechanisms of activation of mechanosensitive receptors that may be involved in the generation of nociceptive signals and migraine associated clinical symptoms. The gender differences of targeting these receptors as potential therapeutic interventions are also acknowledged as well as the challenges related to respective drug development.
CONCLUSIONS: Overall, this analysis identified key molecular players and uncovered significant gaps in our understanding of mechanotransduction in migraine. This review offers a foundation for filling these gaps and suggests novel therapeutic options for migraine treatments based on achievements in the emerging field of mechano-neurobiology.
The pathological mechanisms underlying the sex-dependent presentation of calcific aortic stenosis (AS) remain poorly understood. We aim to analyse sex-specific responses of valve interstitial cells (VICs) to calcific environments and to identify new pathological and potentially druggable targets. First, VICs from stenotic patients were modelled using pro-calcifying media (HP). Both male and female VICs were inflamed upon calcific HP challenge, although the inflammatory response was higher in female VICs. The osteogenic and calcification responses were higher in male VICs. To identify new players involved in the responses to HP, proteomics analyses were performed on additional calcifying VICs. Neuropilin-1 (NRP-1) was significantly up-regulated in male calcifying VICs and that was confirmed in aortic valves (AVs), especially nearby neovessels and calcifications. Regardless of the sex, NRP-1 expression was correlated to inflammation, angiogenesis and osteogenic markers, but with stronger associations in male AVs. To further evidence the role of NRP-1, in vitro experiments of silencing or supplementation with soluble NRP-1 (sNRP-1) were performed. NRP-1 silencing or addition of sNRP-1 reduced/mended the expression of any sex-specific response triggered by HP. Moreover, NRP-1 regulation contributed to significantly diminish the baseline enhanced expression of pro-inflammatory, pro-angiogenic and pro-osteogenic markers mainly in male VICs. Validation studies were conducted in stenotic AVs. In summary, pharmacologic targeting of NRP-1 could be used to target sex-specific phenotypes in AS as well as to exert protective effects by reducing the basal expression of pathogenic markers only in male VICs.
Numerous studies have demonstrated that microRNAs (miRNAs) are critically important for the prediction, diagnosis, and characterization of diseases. However, identifying miRNA-disease associations through traditional biological experiments is both costly and time-consuming. To further explore these associations, we proposed a model based on hybrid high-order moments combined with element-level attention mechanisms (HHOMR). This model innovatively fused hybrid higher-order statistical information along with structural and community information. Specifically, we first constructed a heterogeneous graph based on existing associations between miRNAs and diseases. HHOMR employs a structural fusion layer to capture structure-level embeddings and leverages a hybrid high-order moments encoder layer to enhance features. Element-level attention mechanisms are then used to adaptively integrate the features of these hybrid moments. Finally, a multi-layer perceptron is utilized to calculate the association scores between miRNAs and diseases. Through five-fold cross-validation on HMDD v2.0, we achieved a mean AUC of 93.28%. Compared with four state-of-the-art models, HHOMR exhibited superior performance. Additionally, case studies on three diseases-esophageal neoplasms, lymphoma, and prostate neoplasms-were conducted. Among the top 50 miRNAs with high disease association scores, 46, 47, and 45 associated with these diseases were confirmed by the dbDEMC and miR2Disease databases, respectively. Our results demonstrate that HHOMR not only outperforms existing models but also shows significant potential in predicting miRNA-disease associations.
The present invention relates to inhibiting peptide of a YMDD functional domain of polymerase protein of a hepatitis B virus and application, and the present invention belongs to the field of molecular biology and biochemistry of biotechnology. The short peptide of a YMDD functional domain of polymerase protein of a hepatitis B virus is used as a target site, and peptide which is in specific binding with the target site is screened with the technology of phage display. The amino acid sequences if three kinds of inhibiting peptide screened in the present invention respectively are trptry the asn asn ser the, gly pro phe asn asn pro pro and gly trp leu pro pro pro asp. Through experimental verification, the three kinds of inhibiting peptide screened in the present invention have obvious inhibiting actions on the DNA of an HBV. The present invention provides a novel effective medicine resource for the preparation of anti-HBV medicines. Relative to the existing nucleotide medicines acting on blocking the synthesis of HBV DNA. The inhibiting peptide of the present invention fundamentally inhibites the duplication of HBVs and has supplementary actions with the existing lamivudine type medicines. The inhibiting peptide is suitable for the development of anti-HBV medicines and the molecular virology study of HBVs.
OBJECTIVE: To evaluate in-hospital fees and surgical outcomes of robot-assisted radical cystectomy (RARC), laparoscopic radical cystectomy (LRC) and open radical cystectomy (ORC) using a Japanese nationwide database.
METHODS: All data were obtained from the Diagnosis Procedure Combination database between April 2020 and March 2022. Basic characteristics and perioperative indicators, including in-hospital fees, were compared among the RARC, LRC and ORC groups. Propensity score-matched comparisons were performed to assess the differences between RARC and ORC.
RESULTS: During the study period, 2931, 1311 and 2435 cases of RARC, LRC and ORC were identified, respectively. The RARC group had the lowest in-hospital fee (median: 2.38 million yen), the shortest hospital stay (26 days) and the lowest blood transfusion rate (29.5%), as well as the lowest complication rate (20.9%), despite having the longest anesthesia time (569 min) among the three groups (all P < 0.01). The outcomes of LRC were comparable with those of RARC, and the differences in these indicators between the RARC and ORC groups were greater than those between the RARC and LRC groups. In propensity score-matched comparisons between the RARC and ORC groups, the differences in the indicators remained significant (all P < 0.01), with an ~50 000 yen difference in in-hospital fees.
CONCLUSIONS: RARC and LRC were considered to be more cost-effective surgeries than ORC due to their superior surgical outcomes and comparable surgical fees in Japan. The widespread adoption of RARC and LRC is expected to bring economic benefits to Japanese society.
Daily Fermented Soy (two 12.5g packets/day) (\~1 ounce/day) taken between the time of enrollment and radical prostatectomy (RP). Clinical assessment of both groups will take place 1) at baseline, and 2) just prior to RP, estimated at between 4 and 10 weeks from baseline/enrollment. Length of time in the study will vary for each subject, depending on how far out their prostatectomy will occur; all prostatectomies will be scheduled to occur between 4-10 weeks post-baseline.
Primary open angle glaucoma is a chronic progressive neurodegenerative disease and the only proven effective therapy involves reduction of intraocular pressure (IOP). Although treatment effect is quite large, a significant proportion of patients show disease progression with apparently controlled IOP. Given the similarities with other neurodegenerative diseases - particularly in the mechanisms of cell death -neuroprotective treatments have been tried also in glaucoma. Interesting results from experimental studies and weak evidence from human glaucoma trials have been published in recent years. Citicoline is one of the promising molecules with a putative neuroprotective action and has been tried on patients with a number of neurodegenerative diseases with encouraging results. Pilot studies on glaucomatous patients showed a possible effect of citicoline in reducing progression of visual field changes, though these findings need to be confirmed by larger randomized clinical trials.

The aim of this randomized, double-masked, placebo-controlled, cross-over study is to test whether the intake of Neurotidine® (citicoline free acid in oral solution) can be associated with an improvement of quality of life in patients with glaucoma.
The efficacy of almotriptan tablets in adolescent patients age 12 to 17 years was evaluated in a double-blind, randomized, placebo-controlled study. Patients enrolled in that study had at least a 1-year history of migraine attacks with or without aura usually lasting 4 hours or more (when untreated). Patients enrolled in the study were primarily females (60%) and Caucasian (75%), while 15% of patients were black, and 10% were of other races. Patients were instructed to treat a moderate to severe migraine headache. Two hours after taking one dose of study medication, patients evaluated their headache pain. Associated symptoms of nausea, photophobia, and phonophobia were also evaluated.

In this study, the percentage of patients achieving a pain relief response (mild or no pain) 2 hours after treatment was statistically significantly greater in patients who received almotriptan tablets 6.25 mg or 12.5 mg compared with those who received placebo. There was no additional benefit on pain relief provided by the 12.5 mg dose. The 2-hour pain relief results are summarized in Table 4.

The estimated probability of achieving pain relief within 2 hours following initial treatment with almotriptan tablets in adolescents age 12 to 17 years is shown in Figure 3.

Figure 3. Estimated Probability of Achieving an Initial Headache Response (Mild or No Pain) in 2 Hours in the Adolescent Study 

The prevalence of the migraine-associated symptoms (nausea, photophobia, and phonophobia) at 2 hours after taking the dose was not significantly different between patients who received almotriptan tablets 6.25 mg or 12.5 mg and those who received placebo.
Lower limb muscles of both legs were simultaneously stimulated using self adhesive surface rectangular electrodes. During all session period, the patients were maintained in the supine Fowler 45º position. The stimulation intensity was progressively increased according to the patient tolerance until a muscular contraction was observed. Stimulation was performed twice a day; the session duration was 60 min. Heart rate, blood pressure, respiratory rate and pulse oximetry were monitored throughout the sessions, in all patients.
BACKGROUND: People live longer, and frailty has become an important problem in the acute hospital setting. Increasingly the association between frailty and hospital-acquired complications has been reported. However, the overall burden of frailty in this setting has not been described. Therefore, we undertook this study to describe the association between frailty and the risk of hospital-acquired complications among older adults across our five acute hospitals and to estimate the overall burden of frailty attributable to these complications.
METHODS: Consecutive admissions among women and men aged ≥ 65 years across our local health district's five acute hospitals, between January 2010 and December 2020, were included to investigate the association between the number of cumulative frailty deficit items and hospital-acquired complications and infections. The numbers of cumulative frailty deficits are presented in four groups (0-1 item, 2 items, 3 items, and 4-13 items). Individual events such as falls, delirium, pressure injuries, thromboembolism, malnutrition, and multiple types of infections are also presented. The overall burden of frailty was estimated using a population-attributable-risk approach.
RESULTS: During the study period there were 4,428 hospital-acquired complications, among 120,567 older adults (52% women). The risk of any hospital-acquired complication (HAC) or any hospital-acquired infection (HAI) increased as the cumulative number of frailty deficits increased. For the 0-1 deficit item group versus the 4-13 items group, the risk of any HAC increased from 5.5/1000 admissions to 80.0/1000 admissions, and for any HAI these rates were 6.2/1000 versus 58.2/1000, respectively (both p-values < 0.001). The 22% (27,144/120,567) of patients with 3 or more frailty deficit items accounted for 63% (2,774/4,428) of the combined hospital-acquired complications and infections. We estimated that the population-attributable risks of any hospital-acquired complication or infection were 0.54 and 0.47, respectively.
CONCLUSION: We found that an increasing number of cumulative frailty deficit items among older patients are associated with a higher risk of hospital-acquired complications or infections. Importantly, frail older adults account for most of these adverse events.
* Advise patients and their household members to dispose of any unopened packs remaining from a prescription as soon as they are no longer needed.
  * Instruct patients that, to dispose of any unused ABSTRAL tablets, remove them from the blister cards and flush them down the toilet. Do not dispose of the ABSTRAL blister cards or cartons down the toilet.
  * Detailed instructions for the proper storage, administration, disposal, and important instructions for managing an overdose of ABSTRAL are provided in the ABSTRAL Medication Guide. Ensure patients read this information in its entirety and give them an opportunity to have their questions answered.
  * In the event that a caregiver requires additional assistance in disposing of excess units that remain in the home after the drug is no longer needed, instruct them to call the toll-free number for ProStrakan, Inc. 1-888-227-8725 or seek assistance from their local DEA office.
The efficacy of KRYSTEXXA was studied in adult patients with chronic gout refractory to conventional therapy in two replicate, multicenter, randomized, double-blind, placebo-controlled studies of six months duration: Trial 1 and Trial 2. Patients were randomized to receive KRYSTEXXA 8 mg every 2 weeks or every 4 weeks or placebo in a 2:2:1 ratio. Studies were stratified for the presence of tophi. Seventy-one percent (71%) of patients had baseline tophi. All patients were prophylaxed with an oral antihistamine, intravenous corticosteroid and acetaminophen. Patients also received prophylaxis for gout flares with non-steroidal anti-inflammatory drugs (NSAIDs) or colchicine, or both, beginning at least one week before KRYSTEXXA treatment unless medically contraindicated or not tolerated. Patients who completed the randomized clinical trials were eligible to enroll in a 2-year open label extension study.

Entry criteria for patients to be eligible for the trials were: baseline serum uric acid (SUA) of at least 8 mg/dL; had symptomatic gout with at least 3 gout flares in the previous 18 months or at least 1 gout tophus or gouty arthritis; and had a self-reported medical contraindication to allopurinol or medical history of failure to normalize uric acid (to less than 6 mg/dL) with at least 3 months of allopurinol treatment at the maximum medically appropriate dose.

The mean age of study subjects was 55 years (23-89); 82% were male, mean body mass index (BMI) was 33 kg/m2, mean duration of gout was 15 years, and mean baseline SUA was 10 mg/dL.

To assess the efficacy of KRYSTEXXA in lowering uric acid, the primary endpoint in both trials was the proportion of patients who achieved plasma uric acid (PUA) less than 6 mg/dL for at least 80% of the time during Month 3 and Month 6. As shown in Table 2, a greater proportion of patients treated with KRYSTEXXA every 2 weeks achieved urate lowering to below 6 mg/dL than patients receiving placebo. Although the 4 week regimen also demonstrated efficacy for the primary endpoint, this regimen was associated with increased frequency of anaphylaxis and infusion reactions and less efficacy with respect to tophi.

The effect of treatment on tophi was a secondary efficacy endpoint and was assessed using standardized digital photography, image analysis, and a Central Reader blinded to treatment assignment. Approximately 70% of patients had tophi at baseline. A pooled analysis of data from Trial 1 and Trial 2 was performed as pre-specified in the protocols. At Month 6, the percentage of patients who achieved a complete response (defined as 100% resolution of at least one target tophus, no new tophi appear and no single tophus showing progression) was 45%, 26%, and 8%, with KRYSTEXXA 8 mg every 2 weeks, KRYSTEXXA 8 mg every 4 weeks, and placebo, respectively. The difference between KRYSTEXXA and placebo was statistically significant for the every 2 week dosing regimen, but not for the every 4 week dosing regimen.